R1 Therapeutics develops first‑in‑class kidney disease medicines, beginning with its lead candidate AP306 for hyperphosphatemia in chronic kidney disease patients. AP306 is a pan‑phosphate transporter inhibitor that blocks active phosphate transport, aiming to lower phosphate levels quickly while dramatically reducing the daily pill burden compared with existing binders. The company focuses on delivering new therapeutic options across the full spectrum of renal care.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with chronic kidney disease often develop hyperphosphatemia, a condition that requires daily intake of 9–15 phosphate‑binding pills. Existing treatments are poorly tolerated and fail to normalize serum phosphate in more than 40% of U.S. patients, leading to complications and reduced quality of life.
Solution
R1 Therapeutics is developing AP306, a first‑in‑class pan phosphate transporter inhibitor that blocks the active transport of phosphate in the gut. By targeting three key transporters (NaPi‑IIb, PiT‑1, PiT‑2), AP306 aims to lower serum phosphate rapidly with a single daily dose, dramatically reducing pill burden. The monotherapy is designed for patients with chronic kidney disease on dialysis, offering a more tolerable and effective alternative to current binders. R1’s approach seeks to improve adherence, achieve better phosphate control, and ultimately enhance patient outcomes across the renal care continuum.
Target Audience
Primary customers are nephrologists and dialysis centers treating chronic kidney disease patients with hyperphosphatemia, as well as healthcare systems seeking more tolerable phosphate‑lowering therapies.
Features
- Pan phosphate transporter inhibition blocking NaPi‑IIb, PiT‑1, and PiT‑2 active transport pathways
- Single‑dose oral formulation intended to replace 9–15 daily phosphate‑binding pills
- Rapid reduction of serum phosphate levels demonstrated in preclinical models
- Designed as a monotherapy for hyperphosphatemia in dialysis‑dependent chronic kidney disease patients
- First‑in‑class mechanism distinct from existing phosphate binders, addressing a long‑standing therapeutic gap